Roche Redefines Global Coagulation Diagnostics The market leader of in vitro diagnostics heralds new era
04 October 2011
With a number of industry firsts and innovative applications for early disease detection and monitoring, including a market leadership position in point of care coagulation management, Roche is now rapidly moving towards a new comprehensive offering for the central coagulation laboratory. From easy low volume self-monitoring and professional monitoring at the physician’s office to high efficiency demands of commercial laboratories, Roche is prepared to deliver platforms that deliver outstanding productivity while reducing complexity by addressing current and future testing requirements across a broad range of customer segments.
Consistent with Roche’s current instrument solutions and driven by the company’s commitment to deliver customer driven, quality oriented and cost effective solutions, Roche will enter into a new era of testing solutions for coagulation customers.
Consequently, Roche Diagnostics and Diagnostica Stago announced today that the companies have decided to pursue separate paths in laboratory coagulation in territories where Roche presently distributes the Stago product range. This becomes effective January 1, 2012. During a three year transition period, Roche will continue to supply existing reagent rental customers with Stago reagents as well as service and support. Local exceptions may apply. Notably, Roche Diagnostics Japan will continue to distribute the Stago portfolio within the Japanese market under a separate agreement.
Concurrent with our global presence and commitment in offering total testing solutions, Roche’s new product portfolio will be available globally. Roche’s distinctiveness and unique capabilities combined with a broad array of technologies available positions Roche to further strengthen its leadership position and deliver value to customers and patients worldwide.
The company is making significant investments into its own new hemostasis portfolio that includes two new system families and a full portfolio of compatible assays. Roche is committed to continue with these investments to ensure that the company responds to emerging needs of the central lab coagulation market.
Starting in 2012 Roche will provide customers with two novel platforms to serve low to high throughput requirements together with a comprehensive menu of assays. Ease of use, reliability and cost effectiveness will meet the demands of today`s cost conscious hemostasis laboratories.
From 2014 these platforms will be joined by a second system family with three groundbreaking platforms for all customer segments including our highest throughput customers with a complete menu of coagulation assays.
The laboratory coagulation is estimated at 1330 Mio USD in 2010 with a projected annual growth rate of 5.1% over the course of the next five years. Global trends show an increased demand for routine and special testing while laboratories consolidate, centralize and automate processes based on cost pressures. At the same time, aging populations, rising healthcare costs, advances in science and the many unmet medical needs in the field of hemostasis fuel the need for improved patient outcomes. Combined they will continue to shape Roche’s development pipeline. Uniquely positioned, Roche is ready to drive the revaluation of coagulation diagnostics in the years to come.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com